Thrombophilia resident survival guide: Difference between revisions

Jump to navigation Jump to search
Line 36: Line 36:
'''Abbreviations:''' CBC: complete blood count; VTE: Venous thromboembolism; R/O: Rule out; PT: Prothrombin time; PTT: Partial thromboplastin time; INR:  international normalized ratio; ELISA: Enzyme linked immunosorbent assay  
'''Abbreviations:''' CBC: complete blood count; VTE: Venous thromboembolism; R/O: Rule out; PT: Prothrombin time; PTT: Partial thromboplastin time; INR:  international normalized ratio; ELISA: Enzyme linked immunosorbent assay  
{{familytree/start}}
{{familytree/start}}
{{familytree | | | | | | | | | A01 | | | | | |A01='''Suspected [[Thrombophilia]]'''}}
{{familytree | | | | | | | | | | | | | | | A01 | | | | | | | | | | | |A01='''Suspected [[Thrombophilia]]'''}}
{{familytree | | | | | | | | | |!| | | | | | | | }}
{{familytree | | | | | | | | | | | | | | | |!| | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | B01 | | | | | |B01=<div style="float: left; text-align: left">'''1) [[Medical history|History taking]]''':  
{{familytree | | | | | | | | | | | | | | | B01 | | | | | | | | | | | |B01=<div style="float: left; text-align: left">'''1) [[Medical history|History taking]]''':  
*[[Medical history|Personal history]] of:  
*[[Medical history|Personal history]] of:  
**[[Venous thromboembolism|VTE]]
**[[Venous thromboembolism|VTE]]
Line 54: Line 54:
*[[Prothrombin time|PT]], [[Partial thromboplastin time|PTT]] and [[Prothrombin time|INR]]  
*[[Prothrombin time|PT]], [[Partial thromboplastin time|PTT]] and [[Prothrombin time|INR]]  
}}
}}
{{familytree | | | | | | | | | |!| | | | | | | | }}
{{familytree | | | | | | | | | | | | | | | |!| | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | C01 | | | | | |C01=<div style="float: left; text-align: left">'''Determine the necessity for [[thrombophilia]] evaluation''':
{{familytree | | | | | | | | | | | | | | | C01 | | | | | | | | | | | |C01=<div style="float: left; text-align: left">'''Determine the necessity for [[thrombophilia]] evaluation''':
Factors that favor a throughout evaluation:
Factors that favor a throughout evaluation:
*Recurrent or unprovoked [[thrombosis]]
*Recurrent or unprovoked [[thrombosis]]
Line 64: Line 64:
*[[Medical history|History]] of [[skin]] [[necrosis]] due to [[Vitamin K antagonist|vitamin K antagonists]] use  
*[[Medical history|History]] of [[skin]] [[necrosis]] due to [[Vitamin K antagonist|vitamin K antagonists]] use  
}}
}}
{{familytree | | | | | | | | | |!| | | | | | | | }}
{{familytree | | | | | | | | | | | | | | | |!| | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | D01 |-|-| D02 |-|-| D03| | |D01=<div style="float: left; text-align: left">'''R/O acquired [[etiology|etiologies]] of [[thrombophilia]], such as:
{{familytree | | | | | | | | | | | | | | | D01 |-|-|-| D02 |-|-|-| D03| | |D01=<div style="float: left; text-align: left">'''R/O acquired [[etiology|etiologies]] of [[thrombophilia]], such as:
*[[Antiphospholipid syndrome]]
*[[Antiphospholipid syndrome]]
*[[Medication|Medications]]
*[[Medication|Medications]]
Line 79: Line 79:
*[[Antiphospholipid syndrome|Antiphospholipid antibodies]] with [[Enzyme linked immunosorbent assay (ELISA)|solid-phase ELISA tests]] to detect [[Antiphospholipid syndrome|anticardiolipin (aCL) antibodies]]  
*[[Antiphospholipid syndrome|Antiphospholipid antibodies]] with [[Enzyme linked immunosorbent assay (ELISA)|solid-phase ELISA tests]] to detect [[Antiphospholipid syndrome|anticardiolipin (aCL) antibodies]]  
}}
}}
{{familytree | | | | | | | | | |!| | | | | | | |!| | | | | | | | }}
{{familytree | | | | | | | | | | | | | | | |!| | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | F01 | | | | | | F03 | | | | | | |F01=<div style="float: left; text-align: left">'''Investigate other common etiologies''':
{{familytree | | | | | | | | | F01 | | | | | | F03 | | | | | | |F01=<div style="float: left; text-align: left">'''Investigate other common etiologies''':
*Defect or reduction in natural [[anticoagulant]] system such as [[protein C]] and [[protein S]]
*Defect or reduction in natural [[anticoagulant]] system such as [[protein C]] and [[protein S]]

Revision as of 21:34, 8 November 2020


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anahita Deylamsalehi, M.D.[2]

Synonyms and keywords:Approach to thrombophilia, Thrombophilia workup, Thrombophilia diagnostic approach

Overview

Thrombophilia is defined as a predilection for clot formation (thrombosis). It could be inherited/genetical or acquired, nevertheless most of the time thrombophilia is due to an interplay between both inherited and acquired factors. Protein C deficiency is the most common cause of inherited thrombophilia. This clot formation tendency can lead to venous or arterial thrombus formation and subsequent conditions such as pulmonary embolism, deep venous thrombosis, pregnancy loss, severe pre-eclampsia, myocardial infarction and stroke. Most of patients with thrombophilia may remain asymptomatic until another thrombophilic condition has been added and patients with more than one inherited/genetical defects carry higher chance of thrombus formation. symptoms are generally depended on organ that is involved.

Causes

Known causes of thrombophilia include:[1][2][3][4][5][6]

Diagnosis

Shown below is an algorithm summarizing the diagnosis of thrombophilia.[7][8][9][10][11]

Abbreviations: CBC: complete blood count; VTE: Venous thromboembolism; R/O: Rule out; PT: Prothrombin time; PTT: Partial thromboplastin time; INR: international normalized ratio; ELISA: Enzyme linked immunosorbent assay

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Suspected Thrombophilia
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Determine the necessity for thrombophilia evaluation:

Factors that favor a throughout evaluation:

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the present of features such as:
  • Venous/arterial thromboembolic diseases and adverse pregnancy outcomes such as unexplained miscarriage and/or preterm birth due to pre-eclampsia or placental insufficiency
  • AND

     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    Investigate other common etiologies:
     
     
     
     
     
    {{{ F03 }}}
     
     
     
     
     
     

    Treatment

    Shown below is an algorithm summarizing the treatment of [[disease name]] according the the [...] guidelines.

     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     

    Do's

    Don'ts

    References

    1. Khan S, Dickerman JD (2006). "Hereditary thrombophilia". Thromb J. 4: 15. doi:10.1186/1477-9560-4-15. PMC 1592479. PMID 16968541.
    2. Femi-Akinlosotu OM, Shokunbi MT (2020). "Changes in Neuronal Density of the Sensorimotor Cortex and Neurodevelopmental Behaviour in Neonatal Mice with Kaolin-Induced Hydrocephalus". Pediatr Neurosurg: 1–10. doi:10.1159/000510603. PMID 33108787 Check |pmid= value (help).
    3. Rey E, Kahn SR, David M, Shrier I (2003). "Thrombophilic disorders and fetal loss: a meta-analysis". Lancet. 361 (9361): 901–8. doi:10.1016/S0140-6736(03)12771-7. PMID 12648968.
    4. Wun T, Brunson A (2016). "Sickle cell disease: an inherited thrombophilia". Hematology Am Soc Hematol Educ Program. 2016 (1): 640–647. doi:10.1182/asheducation-2016.1.640. PMC 6142455. PMID 27913540.
    5. Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R; et al. (2005). "Diagnosis and management of paroxysmal nocturnal hemoglobinuria". Blood. 106 (12): 3699–709. doi:10.1182/blood-2005-04-1717. PMC 1895106. PMID 16051736.
    6. McMahon C, Abu-Elmagd K, Bontempo FA, Kant JA, Swerdlow SH (2007). "JAK2 V617F mutation in patients with catastrophic intra-abdominal thromboses". Am J Clin Pathol. 127 (5): 736–43. doi:10.1309/JA1WD8JNVLGYNQYE. PMID 17439832.
    7. Marlar RA, Gausman JN (2011). "Protein S abnormalities: a diagnostic nightmare". Am J Hematol. 86 (5): 418–21. doi:10.1002/ajh.21992. PMID 21523802.
    8. 8.0 8.1 8.2 8.3 Lybeck A, Friberg H, Nielsen N, Rundgren M, Ullén S, Zetterberg H; et al. (2020). "Postanoxic electrographic status epilepticus and serum biomarkers of brain injury". Resuscitation. doi:10.1016/j.resuscitation.2020.10.027. PMID 33127439 Check |pmid= value (help).
    9. 9.0 9.1 9.2 Ballard RB, Marques MB, Education Committee of the Academy of Clinical Laboratory Physicians and Scientists (2012). "Pathology consultation on the laboratory evaluation of thrombophilia: when, how, and why". Am J Clin Pathol. 137 (4): 553–60. doi:10.1309/AJCP5SQT3ZKYQFBM. PMID 22431530.
    10. Cattaneo M, Chantarangkul V, Taioli E, Santos JH, Tagliabue L (1999). "The G20210A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis: prevalence and association with factor V G1691A, methylenetetrahydrofolate reductase C677T and plasma prothrombin levels". Thromb Res. 93 (1): 1–8. doi:10.1016/s0049-3848(98)00136-4. PMID 10065893.
    11. Baglin T, Gray E, Greaves M, Hunt BJ, Keeling D, Machin S; et al. (2010). "Clinical guidelines for testing for heritable thrombophilia". Br J Haematol. 149 (2): 209–20. doi:10.1111/j.1365-2141.2009.08022.x. PMID 20128794.
    12. 12.0 12.1 Bauer KA (2003). "Management of thrombophilia". J Thromb Haemost. 1 (7): 1429–34. doi:10.1046/j.1538-7836.2003.00274.x. PMID 12871277.
    13. Ginsberg JS, Hirsh J (1989). "Anticoagulants during pregnancy". Annu Rev Med. 40: 79–86. doi:10.1146/annurev.me.40.020189.000455. PMID 2658763.


    Template:WikiDoc Sources